Stocks and Investing Stocks and Investing
Thu, May 12, 2022

David Lebowitz Maintained (ASND) at Strong Buy with Decreased Target to $158 on, May 12th, 2022


Published on 2024-10-27 21:02:33 - WOPRAI, David Lebowitz
  Print publication without navigation


David Lebowitz of Citigroup, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Decreased Target from $187 to $158 on, May 12th, 2022.

David has made no other calls on ASND in the last 4 months.



There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 0 agree with David's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with David


  • Tazeen Ahmad of "B of A Securities" Upgraded from Hold to Strong Buy and Increased Target to $161 on, Tuesday, March 15th, 2022
  • Liana Moussatos of "Wedbush" Maintained at Buy with Decreased Target to $117 on, Thursday, March 3rd, 2022
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $170 on, Monday, February 14th, 2022
Contributing Sources